Basilea Pharmaceutica (BSLN) Price & Analysis

Compare

4 Followers

BSLN Stock Chart & Stats

Day’s Range― - ―

52-Week RangeCHF37.50 - CHF59.70

Previous CloseN/A

Volume30.09K

Average Volume (3M)44.85K

Market Cap

CHF570.66M

Enterprise ValueCHF614.24M

Total Cash (Recent Filing)CHF120.71M

Total Debt (Recent Filing)CHF111.67M

Price to Earnings (P/E)7.8

Beta1.01

Next Earnings

Feb 17, 2026

EPS Estimate

3.07

Last Dividend Ex-Date

Apr 11, 2013

Dividend YieldN/A

Share Statistics

EPS (TTM)1.26

Shares Outstanding13,318,449

10 Day Avg. Volume35,623

30 Day Avg. Volume44,851

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

CHF84.50

Price Target Upside81.72% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Financial PerformanceCresemba achieved a 20% year-over-year growth in global in-market sales, making it the largest branded antifungal for invasive fungal infections worldwide.

Pipeline DevelopmentBasilea announced the initiation of FORWARD-IM, a Phase 3 registrational study evaluating the efficacy and safety of its broad-spectrum antifungal fosmanogepix for the treatment of adult patients with invasive mold infections.

Regulatory ApprovalThe FDA approved Zevtera for three specific indications; it is the only FDA-approved methicillin-resistant Staphylococcus aureus (MRSA) cephalosporin antibiotic for treating adult patients with S. aureus bloodstream infections (bacteremia) and endocarditis.

Bears Say

Expense ManagementFailure to maintain appropriate expense control to achieve sustainable profitability is a significant risk for Basilea.

Market Penetration RisksRisks include inability by Basilea's partners to optimize the value of isavuconazole and ceftobiprole globally, and setbacks with clinical-stage candidates, notably fosmanogepix.

Basilea Pharmaceutica News

Basilea’s Phase 3 Study on Fosmanogepix: A Potential Game-Changer in Antifungal Treatment

Basilea Pharmaceutica (($CH:BSLN)) announced an update on their ongoing clinical study. Basilea Pharmaceutica is conducting a Phase 3...

2d ago

BSLN

Basilea Pharmaceutica’s Earnings Call Highlights Growth and Challenges

Basilea Pharmaceutica (($CH:BSLN)) has held its Q2 earnings call. Read on for the main highlights of the call....

9d ago

Basilea Pharmaceutica’s Phase 3 Study on Fosmanogepix: A Potential Game-Changer in Antifungal Treatment

Basilea Pharmaceutica (($CH:BSLN)) announced an update on their ongoing clinical study. Basilea Pharmaceutica is conducting a Phase 3...

11d ago

BSLN

Basilea Pharmaceutica Reports Strong Financial Growth and Strategic Milestones in H1 2025

Basilea Pharmaceutica ( ($CH:BSLN) ) just unveiled an update. Basilea Pharmaceutica reported a significant financial performance in the...

22d ago

Basilea Pharmaceutica’s Phase 3 Trial: A Potential Game-Changer in Antifungal Treatment

DEL_Basilea Pharmaceutica (($DEL_0QNA)), Basilea Pharmaceutica (($CH:BSLN)) announced an update on their ongoing clinical study. Study Overview: Basilea Pharmaceutica...

26d ago

Basilea Pharmaceutica Expands Pipeline with New Antibiotic License

Basilea Pharmaceutica ( ($CH:BSLN) ) just unveiled an announcement. Basilea Pharmaceutica has entered into an exclusive license agreement...

27d ago

Basilea Pharmaceutica’s Phase 3 Study on Fosmanogepix: A Potential Game-Changer in Antifungal Treatments

DEL_Basilea Pharmaceutica (($DEL_0QNA)), Basilea Pharmaceutica (($CH:BSLN)) announced an update on their ongoing clinical study. Study Overview: Basilea Pharmaceutica...

28d ago

Basilea Pharmaceutica’s Phase 3 Study on Fosmanogepix: A Potential Game-Changer for Mold Infections

DEL_Basilea Pharmaceutica (($DEL_0QNA)), Basilea Pharmaceutica (($CH:BSLN)) announced an update on their ongoing clinical study. Study Overview: Basilea Pharmaceutica...

1M ago

Basilea Pharmaceutica Completes Phase 1 Study of Fosmanogepix: Implications for Investors

DEL_Basilea Pharmaceutica (($DEL_0QNA)), Basilea Pharmaceutica (($CH:BSLN)) announced an update on their ongoing clinical study. Study Overview: Basilea Pharmaceutica...

1M ago

Basilea’s Phase 3 Study on Fosmanogepix: A Potential Game-Changer for Mold Infections

DEL_Basilea Pharmaceutica (($DEL_0QNA)), Basilea Pharmaceutica (($CH:BSLN)) announced an update on their ongoing clinical study. Study Overview: Basilea Pharmaceutica...

1M ago

BSLN FAQ

What was Basilea Pharmaceutica’s price range in the past 12 months?

Basilea Pharmaceutica lowest stock price was CHF37.50 and its highest was CHF59.70 in the past 12 months.

What is Basilea Pharmaceutica’s market cap?

Basilea Pharmaceutica’s market cap is CHF570.66M.

When is Basilea Pharmaceutica’s upcoming earnings report date?

Basilea Pharmaceutica’s upcoming earnings report date is Feb 17, 2026 which is in 161 days.

How were Basilea Pharmaceutica’s earnings last quarter?

Basilea Pharmaceutica released its earnings results on Aug 19, 2025. The company reported CHF1.26 earnings per share for the quarter, missing the consensus estimate of CHF2.03 by -CHF0.77.

Is Basilea Pharmaceutica overvalued?

According to Wall Street analysts Basilea Pharmaceutica’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Basilea Pharmaceutica pay dividends?

Basilea Pharmaceutica pays a Notavailable dividend of CHF5 which represents an annual dividend yield of N/A. See more information on Basilea Pharmaceutica dividends here

What is Basilea Pharmaceutica’s EPS estimate?

Basilea Pharmaceutica’s EPS estimate is 3.07.

How many shares outstanding does Basilea Pharmaceutica have?

Basilea Pharmaceutica has 13,318,449 shares outstanding.

What happened to Basilea Pharmaceutica’s price movement after its last earnings report?

Basilea Pharmaceutica reported an EPS of CHF1.26 in its last earnings report, missing expectations of CHF2.03. Following the earnings report the stock price went down -7.561%.

Which hedge fund is a major shareholder of Basilea Pharmaceutica?

Currently, no hedge funds are holding shares in CH:BSLN

Company Description

Basilea Pharmaceutica

Basilea Pharmaceutica AG is a biopharmaceutical company based in Switzerland that focuses on the development and commercialization of innovative therapies for oncology and infectious diseases. The company specializes in the discovery and development of novel antimicrobial agents and targeted cancer treatments, with a particular emphasis on addressing unmet medical needs in these areas. Its core products include a range of antibiotics and oncology drugs that target specific molecular pathways involved in disease progression.

Basilea Pharmaceutica (BSLN) Earnings & Revenues

Historic Earnings Reports

BSLN Stock 12 Month Forecast

Average Price Target

CHF84.50

▲(81.72% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"38":"CHF38","101":"CHF101","53.75":"CHF53.8","69.5":"CHF69.5","85.25":"CHF85.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF100.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":84.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF84.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":69,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF69.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[38,53.75,69.5,85.25,101],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,46.85,50.93846153846154,55.026923076923076,59.11538461538461,63.20384615384616,67.29230769230769,71.38076923076923,75.46923076923076,79.5576923076923,83.64615384615385,87.73461538461538,91.82307692307691,95.91153846153847,{"y":100,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,46.85,49.746153846153845,52.642307692307696,55.53846153846154,58.434615384615384,61.330769230769235,64.22692307692307,67.12307692307692,70.01923076923077,72.91538461538462,75.81153846153846,78.70769230769231,81.60384615384615,{"y":84.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,46.85,48.55384615384615,50.25769230769231,51.96153846153846,53.66538461538462,55.36923076923077,57.073076923076925,58.776923076923076,60.48076923076923,62.184615384615384,63.88846153846154,65.59230769230768,67.29615384615384,{"y":69,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":39.75,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.2,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.6,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.95,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.35,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.7,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.15,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.05,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.2,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.6,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.85,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >